Development in multicellular organisms is guided by tightly regulated waves of gene expression. These waves or pulses ensure that cells activate the proper genetic programs in a sequential order, each pulse corresponding to a critical developmental checkpoint. Prior research by Hammell’s group revealed the existence of such pulsatile gene expression driving the developmental timeline in C. elegans, but the precise mechanism by which these pulses were initiated and terminated remained enigmatic. The latest research demystifies this puzzle, highlighting the pivotal roles of two proteins—MYRF-1 and LIN-42—that constitute a feedback circuit embodying the worm’s internal developmental clock.

This molecular timer serves as a ratchet-like system. It imposes an irreversible forward progression through four defined larval stages by ensuring that the activation of developmental genes occurs in a fixed, linear sequence and that each stage lasts for the correct duration without repetition. Unlike traditional biological clocks, such as circadian rhythms which cycle repeatedly, this developmental clock is uniquely programmed for a finite series of events that happen only once during the organism’s life cycle. This programming guarantees orderly cellular maturation and organismal growth.

Fundamental to this timer’s operation is MYRF-1, a transcription factor previously recognized for diverse roles but now identified as the master initiator of developmental pulses. Using a combination of classical molecular biology techniques, advanced DNA and protein sequencing, and structural modeling with the AI tool AlphaFold, the team elucidated that MYRF-1 functions as the “starting gun”—triggering the onset of each gene expression pulse at the appropriate developmental stage. Furthermore, MYRF-1 is also indispensable for the critical developmental checkpoint signaling where one larval stage ends and the next begins.

Beyond initiation, MYRF-1 activates LIN-42, a protein that fine-tunes the pulse dynamics by dictating the strength and duration of gene expression waves. LIN-42’s modulation ensures that each pulse is neither prematurely terminated nor excessively prolonged, factors crucial for successful transition through developmental stages. Disrupting MYRF-1, the researchers found, resulted in a breakdown of this temporal control mechanism, halting development and underscoring the protein’s essential regulatory role.

Equally fascinating is the finding that this clock circuit operates ubiquitously across all cells, synchronizing developmental timing at an organism-wide scale. The synchronous ticking of independent cellular clocks points to an intercellular communication system coordinating these molecular timekeepers—a subject that remains largely unexplored but holds significant promise for understanding how multicellular organisms harmonize complex developmental processes.

This intricate interplay between MYRF-1 and LIN-42 introduces a paradigm shift, not only enriching our comprehension of developmental biology but also fueling inquiries into how temporal identities at the cellular level couple with developmental checkpoints. Such timing mechanisms could offer fresh perspectives on developmental disorders, where misregulation of temporal progression leads to disease, as well as informing regenerative medicine strategies that require precise control over cell differentiation pathways.

Moreover, the discovery opens avenues for biotechnological innovation. By manipulating molecular timers, it may become feasible to regulate developmental stages artificially, potentially enhancing worm models used to study genetics, neurobiology, and aging. The demonstration that AI tools like AlphaFold can uncover structural and functional protein insights accelerates this research, highlighting the synergy between computational biology and experimental techniques in unraveling life’s complexities.

Leemor Joshua-Tor, Director of Research at CSHL and a collaborator on the project, emphasizes the next steps: dissecting the physical interaction between MYRF-1 and LIN-42, and elucidating how these molecular clocks communicate intercellularly to maintain developmental fidelity. Solving these mysteries may redefine our understanding of multicellular development and temporal coordination at a molecular level.

In essence, the study reveals the delicate clockwork that drives C. elegans from larva to adult—a process reliant on an exquisite molecular timer that, once set in motion, ensures forward developmental progression without retracing steps. This ratchet-like system exemplifies biological precision, reminding us that the temporal dimension of gene regulation is as vital as the genetic code itself.

The implications of this research stretch far beyond nematodes. Developmental timing is a universal challenge across life forms. Understanding how these non-repeating biological clocks are encoded at the molecular level offers a blueprint for interpreting complex developmental schedules, with potential ramifications in fields ranging from developmental genetics to evolutionary biology and medicine.

As the team continues its exploration, one of the most tantalizing questions remains: how do these developmental clocks maintain synchrony across millions of cells, ensuring a harmonious developmental cascade? Unlocking this secret could not only illuminate developmental biology but also provide crucial insights into disorders characterized by disrupted cellular timing, offering hope for interventions that restore the natural rhythm of life to countless individuals.

Subject of Research: Developmental timing and molecular mechanisms regulating gene expression pulses in Caenorhabditis elegans

Article Title: A molecular timer couples organism-wide temporal identity to developmental checkpoints

Web References: DOI link

Image Credits: Cold Spring Harbor Laboratory (CSHL)

Keywords: Developmental timing, Larval stages, Developmental checkpoints, Cell development, Transcription factors, MicroRNA

CTNNB1 encodes β-catenin, a multifunctional protein that regulates not only tissue growth and repair but also cell-to-cell adhesion. Typically, β-catenin levels inside the cell are tightly controlled through a sophisticated degradation mechanism, ensuring its presence precisely when needed. Central to this regulation is a “hotspot” region within CTNNB1, which acts as a molecular tag marking β-catenin for destruction once its role is fulfilled. However, mutations within this hotspot can disrupt this finely tuned balance, precipitating aberrant accumulation of β-catenin and thus promoting unchecked cell proliferation — a defining characteristic of cancer.

Recognizing the enigmatic nature of the diverse mutations present within this hotspot, the researchers embarked upon an ambitious project to systematically evaluate every single possible mutation within this domain. Employing cutting-edge genome-editing technologies in mouse stem cells — chosen for their genomic similarity and highly conserved β-catenin pathways with humans — the researchers generated an unprecedented dataset encompassing all 342 possible single-nucleotide variants. This exhaustive experimental approach allowed them to directly quantify the impact of each mutation on β-catenin’s signaling activity.

Innovatively, the study utilized a fluorescent reporter assay linked to β-catenin signaling, enabling precise measurement of pathway activation in living cells. This methodological ingenuity revealed a broad spectrum of functional consequences across the mutation landscape: while some variants instigated minimal increases in β-catenin activity, others unleashed potent hyperactivation, dramatically amplifying oncogenic signaling. By calibrating these experimental results against genetic data derived from thousands of cancer patients, the team established a robust predictive framework correlating mutation strength with tumor behavior across diverse cancer types.

A particularly striking revelation emerged from dissecting the mutation profiles within hepatocellular carcinoma, a predominant liver cancer. Here, two distinct tumor populations were identified: one harboring CTNNB1 mutations eliciting relatively modest β-catenin activation, and another characterized by mutations generating substantially stronger oncogenic signals. Intriguingly, the tumors with weaker mutations presented higher infiltrates of immune cells, whereas those with potent β-catenin activation exhibited a more immune-evasive microenvironment. This dichotomy not only spotlights the influence of mutation potency on tumor-immune dynamics but also posits mutation strength as a potential proxy for predicting immunotherapy responsiveness.

These insights bear profound implications for precision oncology. The high-resolution mutation map crafted by the researchers offers clinicians a novel tool to anticipate cancer progression trajectories based on tumor-specific CTNNB1 mutations. By enabling nuanced stratification of patients according to β-catenin activation profiles, this work paves the way for tailored therapeutic regimens and fuels the development of targeted drugs designed to modulate β-catenin signaling with enhanced specificity.

Andrew Wood, Principal Investigator at the University of Edinburgh’s Institute of Genetics and Cancer and co-leader of the study, emphasized the transformative potential of the findings: “Our exhaustive analysis is the first to empirically dissect every conceivable mutation within this crucial hotspot. It endows the scientific community with an unprecedented lens through which to examine how β-catenin drives tumorigenesis across a spectrum of cancer types, bolstering efforts to innovate personalized treatment strategies.”

The research was underpinned by strong interdisciplinary collaboration, involving experts from the University of Edinburgh, Leiden University Medical Center, and Koç University. Supported by the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC), the study exemplifies the synergy of experimental precision, computational analytics, and clinical data integration.

By mapping the functional terrain of CTNNB1 mutations in such granular detail, this work addresses a longstanding challenge in cancer genetics — decoding the pathophysiological relevance of specific variants within critical oncogenes. Beyond CTNNB1, it sets a precedent for similar exhaustive mutational explorations in other cancer-related genes, ushering in a new era of comprehensive genotype-to-phenotype correlation.

Moreover, understanding how different mutation-induced β-catenin activities sculpt distinct tumor microenvironments adds a critical dimension to immuno-oncology research. The observed link between mutation strength, immune infiltration, and potential therapeutic responsiveness invites further studies to dissect the mechanistic underpinnings and translate these findings into clinical biomarkers.

Overall, this pioneering research heralds a major leap forward in cancer biology, merging sophisticated genome editing with patient data to unravel the complex interplay between gene mutations and tumor behavior. As the fight against cancer intensifies, tools like this mutation activity map underscore the promise of genomics-driven precision medicine in transforming outcomes for patients worldwide.

Subject of Research: Animals

Article Title: (Not provided)

News Publication Date: 2-Feb-2026

Web References:
https://doi.org/10.1038/s41588-025-02496-5

References:
Wood, A. et al., Nature Genetics, 2026.

Keywords: Health and medicine

The role of nuclear export in cellular processes cannot be overstated; it is an essential mechanism that regulates the transportation of proteins and RNA out of the nucleus. This process is vital for various cellular functions, including gene expression and cellular responses to environmental stimuli. Selinexor operates by inhibiting this export, thereby retaining specific proteins in the nucleus that are crucial for regulating cell growth and migration. Such a mechanism offers an exciting avenue for intervention in conditions characterized by uncontrolled cellular proliferation and migration, such as cancer.

In the study by Öztatlıcı et al., male germ cells were subjected to Selinexor treatment, and a series of assays were conducted to determine the compound’s effects on cell viability and migration. The results were compelling. Selinexor not only reduced the proliferation of male germ cells but also significantly impeded their migratory capabilities. This finding has profound implications, particularly in the context of understanding fertility and the influence of pharmacological agents on male reproductive health.

The significance of such research extends beyond mere cellular biology; it encompasses broader implications for health and medicine. By elucidating the mechanisms through which Selinexor exerts its effects, researchers can begin to formulate strategies for addressing a variety of reproductive and oncological conditions. This link between basic science and potential clinical application is a hallmark of progress in biomedical research and can pave the way for novel therapeutic approaches.

As the scientific community delves deeper into the interplay of pharmacology and reproductive health, the insights gained from studies like these could contribute to developing new treatment protocols for male infertility or improve outcomes for patients undergoing cancer therapies that adversely affect germ cell function. The dual role of Selinexor as both an anti-proliferative and anti-migratory agent underscores the potential for repurposing existing drugs to target new diseases.

In an age where precision medicine is becoming increasingly paramount, the specificity of Selinexor presents a compelling case for its use in targeted therapeutic strategies. Researchers are continuously seeking compounds that can effectively target malignant cells while minimizing harm to surrounding healthy tissues. Selinexor’s selective nature offers a promising alternative, and further exploration could yield valuable insights into its full therapeutic potential.

Moreover, the in vitro nature of this study allows for a controlled environment, where variables can be meticulously managed. This aspect of the research is vital as it establishes a foundational understanding that can later be translated into in vivo studies. Future research should aim to investigate the efficacy of Selinexor in animal models, examining how these results may vary in a more complex biological system.

As studies of this nature progress, they contribute to a growing body of literature emphasizing the need for integrative approaches to understanding male reproductive health. The nuances of germ cell biology must be acknowledged as we move forward; factors such as environmental influences, lifestyle choices, and genetic predispositions all play vital roles in shaping male fertility and health.

At the heart of these discussions is the notion that scientific breakthroughs often stem from understanding fundamental biological processes. Selinexor’s ability to modulate these processes invites further scrutiny and experimentation, urging researchers to explore the implications not only for germ cells but also for other cell types that rely on similar mechanisms.

The research community is abuzz with the promise of compounds like Selinexor. As more studies elucidate its mechanisms and therapeutic applications, the anticipation of a new frontier in pharmacological treatment for reproductive health challenges looms on the horizon. Awareness of such innovative research is crucial, as it encourages funding, collaboration, and public interest in the science behind male reproductive health.

In conclusion, the work conducted by Öztatlıcı and peers is a testament to the innovative spirit of contemporary biomedical research. By shedding light on the anti-proliferative and anti-migratory effects of Selinexor on male germ cells, the team has paved the way for further investigations that could eventually lead to groundbreaking therapeutic strategies benefiting countless individuals facing fertility and health challenges. The intersection of science and practical application is a journey, one that we must collectively embrace as we seek solutions to complex health issues.

The future of this research holds immense promise, and the scientific community stands at the precipice of discovery, equipped with the tools required to navigate the complexities of cellular behavior, pharmacology, and human health. Selinexor represents not just a compound but a beacon of hope for advancements in male reproductive health, offering a glimmer of possibility in an often-overlooked field of study.

As researchers continue to pursue the depth of knowledge surrounding Selinexor and other novel agents, we can anticipate a transformation in our understanding of male fertility and reproductive biology. The quest for answers is ceaseless, but with endeavors such as the one by Öztatlıcı and colleagues, it becomes increasingly clear that we are moving closer to discovering solutions that may one day enhance human health and wellbeing.

Subject of Research: Inhibitory effects of Selinexor on male germ cells

Article Title: Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro.

Article References:

Öztatlıcı, M., Zada, P.R., Çolaksel, R.B. et al. Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro. BMC Pharmacol Toxicol 26, 196 (2025). https://doi.org/10.1186/s40360-025-01034-7

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s40360-025-01034-7

Keywords: Selinexor, nuclear export, male germ cells, anti-proliferative, anti-migratory, pharmacology, reproductive health, biomedical research.

One longstanding enigma clarified by this study concerns why RHEB–GTP, the key growth factor-dependent activator of mTORC1, exhibits surprisingly low affinity for mTORC1 in solution. By incorporating physiological concentrations of lipidated RHEB–GTP and anchoring it to liposomal membranes alongside membrane-bound Ragulator and the RAG GTPase dimer, researchers recreated a near-native environment that sharply potentiated mTORC1 kinase activation. This reflects a profound impact of spatial organization: tethering RHEB to the membrane boosts its local concentration around mTORC1, facilitating interaction and activation in a way unattainable in solution. This finding underscores the critical importance of ‘reduction of dimensionality’—the confinement of diffusible molecules to two-dimensional membrane surfaces—which effectively increases the encounter rate between regulators and their targets.

Yet membrane tethering alone could not explain the full extent of mTORC1 activation. High-resolution cryo-EM revealed that both the mTOR kinase itself and the RAPTOR subunit establish direct physical contacts with the lysosomal membrane, prompting sweeping conformational rearrangements across the mTORC1 complex. These allosteric shifts span multiple domains separated by vast molecular distances exceeding 230 angstroms, from the HEAT repeats through the FAT domain to the kinase lobes. Such large-scale remodeling reorients critical kinase elements, fine-tuning the active site geometry to achieve maximal catalytic efficiency. This multi-domain membrane engagement emerges as a central theme in mTORC1 activation, highlighting the lysosomal membrane not merely as a localization platform but as an active allosteric modulator.

In a particularly intriguing extension, membrane shape dynamics appear to contribute meaningfully to mTORC1 regulation. Lysosomes, known to undergo marked tubulation and swelling during their functional cycles and stress responses, potentially influence kinase activation by altering the curvature and tension of the membrane interface. The study’s biochemical reconstitutions demonstrate that mTORC1 activation correlates with liposome shape, suggesting that the mechanical properties of membranes provide an additional regulatory axis modulating the signaling output. Such findings hint at a sophisticated integration of biophysical and biochemical signals in the spatial control of cell growth pathways.

From an evolutionary perspective, the distinctive membrane anchoring mode of mTOR diverges from other PIKK family kinases, which commonly respond to damage signals via localized rearrangements. However, the structural alignments between activated mTORC1 and relatives like ATM, ATR (MEC1), and DNA-PK reveal conserved rearrangements in the kinase active sites, situating mTOR within a broader family of stress-responsive enzymes while also highlighting its unique spatial regulation on membranes. This alignment of ATP binding sites across PIKKs reinforces the functional significance of the membrane-induced conformational transitions discovered.

Furthermore, an unexpected finding emerged with the identification of a second RAG–Ragulator binding site localized on the MLST8 subunit, a component shared between mTORC1 and mTORC2. Intriguingly, this site is sterically occluded in mTORC2 by SIN1, consistent with mTORC2’s lack of interaction with RAG GTPases. The new binding interface also overlaps with the docking site of the inhibitory protein PRAS40, an insulin-responsive antagonist of mTORC1. Although MLST8 is dispensable for mTORC1’s basal activity, the discovery raises compelling questions about how RAG–Ragulator might modulate inhibition by PRAS40 or influence lysosomal recruitment, suggesting additional layers of nuanced regulation.

The integration of nutrient and growth factor signaling on the lysosome emerges through a finely tuned four-step mechanism delineated by this work. Initially, the RAG–Ragulator complex tethers mTORC1 in proximity to the lysosomal membrane within approximately 10 nanometers, creating a spatial microenvironment conducive to subsequent interactions. Next, RHEB–GTP, itself membrane-anchored at variable distances from the membrane, captures mTORC1 within a target zone of roughly 1.5 to 4 nanometers, initiating the hallmark conformational changes indicative of kinase activation. Membrane docking is then driven initially by the RAPTOR ‘finger’ motif, which contacts the membrane in both intermediate and fully active states. Finally, the direct engagement of mTOR’s membrane-interacting site solidifies the fully active conformation, signifying maximal enzymatic output.

This comprehensive structural model reconciles how a transient and spatially restricted pool of RHEB localized on lysosomes can exert powerful control over mTORC1 activity amidst abundant competing cellular signals. By invoking both biochemical specificity and mechanical membrane interactions, it reveals how nutrient availability and growth factor cues converge physically and functionally on mTORC1. Notably, these findings also open new avenues investigating how membrane shape fluctuations and lipid composition dynamically regulate the growth machinery, with implications for understanding lysosomal physiology and pathologies marked by dysregulated mTOR signaling.

Although the current cryo-EM analyses represent major advances compared to previous membrane-free structures, the authors prudently acknowledge the possibility of further structural nuances emerging once atomistic resolution of mTORC1 on native lysosomal membranes in living cells becomes achievable. Such in situ structural elucidations will likely refine our understanding of the precise kinetics and thermodynamics underlying membrane engagement and enzymatic activation. Moreover, the study highlights the value of future biophysical assays—such as single-molecule Förster resonance energy transfer—to dissect the temporal coordination between conformational dynamics and catalytic rates.

An additional unresolved question pertains to how membrane interactions influence mTORC1’s phosphorylation of noncanonical substrates like TFEB, which depend on RAG–Ragulator but not RHEB. The complex interplay between multiple regulatory axes, including these discrete phosphorylation events, underscores the multifaceted nature of mTORC1 as a signaling hub. Further mechanistic insight into these distinct modalities promises to deepen our understanding of how cellular metabolic homeostasis is finely tuned in physiological and pathological states.

Collectively, this study elegantly elucidates the structural logic of mTORC1 activation on the lysosomal membrane, elevating our molecular understanding of a crucial signaling node that governs cell growth and metabolism. By integrating biochemical reconstitution, high-resolution cryo-EM, and mechanistic modeling, the work captures the spatial and dynamic intricacies that enable mTORC1 to serve as a central integrator of nutritional and growth factor signals. These revelations have profound implications, potentially informing targeted modulation of mTOR signaling in cancer, metabolic diseases, and aging.

As researchers continue to unravel the crosstalk between membrane biophysics and kinase activation, this work exemplifies how synergizing structural biology with cellular biochemistry can decode complex signaling circuits. Emerging methods to probe mTORC1 within endogenous lysosomal membranes in live cells, alongside kinetic analyses, will undoubtedly enrich the current model and may catalyze novel therapeutic strategies aimed at fine-tuning mTOR activity with exquisite spatiotemporal control.

Subject of Research: Structural Basis and Mechanism of mTORC1 Activation on the Lysosomal Membrane

Article Title: Structural basis for mTORC1 activation on the lysosomal membrane

Article References:
Cui, Z., Esposito, A., Napolitano, G. et al. Structural basis for mTORC1 activation on the lysosomal membrane. Nature (2025). https://doi.org/10.1038/s41586-025-09545-3

Image Credits: AI Generated

Leveraging an innovative genome-wide CRISPR screening approach, the research team systematically disrupted genes across the entire genome within pre-clinical models of aggressive lymphoma. This unbiased and meticulous method allowed them to evaluate the role of each gene in tumor suppression. Surprisingly, the screening spotlighted the GATOR1 complex as a crucial brake on malignant growth, revealing how loss or dysfunction of its components accelerates lymphoma progression.

The GATOR1 complex functions mainly as a regulatory checkpoint within the mTORC1 signaling pathway, a central hub managing cellular metabolism and proliferation. Under normal conditions, GATOR1 acts to restrain mTORC1 activity, thus preventing uncontrolled growth. However, when genes coding for the GATOR1 complex are absent or mutated, this crucial inhibition fails, unleashing unregulated cellular proliferation which can culminate in the development of tumors such as lymphomas.

This pioneering study was carried out through an interdisciplinary collaboration involving the Olivia Newton-John Cancer Research Institute (ONJCRI), the Walter and Eliza Hall Institute (WEHI), and the Peter MacCallum Cancer Centre. Together, these leading Australian institutions developed sophisticated mouse lymphoma models driven by the overexpression of the MYC oncogene—an aberration implicated in nearly 70% of all human cancers.

The interconnection with MYC is especially significant; MYC is a master regulator of cell cycle and metabolism, driving rapid cancer growth when deregulated. The research illuminates how GATOR1’s suppression of mTORC1 signaling is essential to balance MYC-driven malignancy. Without GATOR1’s braking function, MYC-driven lymphomas expand unchecked, revealing a new molecular vulnerability that could become a target for novel therapies.

One of the most exciting aspects of the findings is the demonstrated sensitivity of GATOR1-deficient lymphomas to existing drugs targeting mTORC1-related pathways. These pharmacological agents, historically exhibiting limited success in cancer treatment, showed marked efficacy in pre-clinical lymphoma models lacking GATOR1 components. This suggests a precision medicine strategy whereby patients with GATOR1 deficiencies could benefit substantially from these therapies.

Dr. Margaret Potts, co-leader of the study, emphasized the power of the unbiased CRISPR screen approach. Unlike traditional research that focuses on known oncogenic pathways, this genome-wide method revealed both anticipated and novel tumor suppressors. The comprehensive nature of this technique heralds a new era in cancer research, where unexpected targets like GATOR1 emerge as promising therapeutic focal points.

Further underscoring the necessity of such studies, lymphoma remains a pressing global health challenge. According to the Global Cancer Observatory, over 630,000 new cases were documented worldwide in 2022 alone. Despite advances in cancer research, the molecular mechanisms driving lymphoma progression have continued to present significant therapeutic hurdles. This work represents a vital method to dissect those complex biological pathways for improved intervention.

Prof. Marco Herold, CEO of ONJCRI and senior author of the paper, highlighted the translational potential of these findings. By elucidating the molecular checks that normally restrain oncogene-driven cancer cell growth, the study bridges fundamental biology with clinical applications. The hope is that tailored therapies exploiting GATOR1 pathway deficiencies could transform patient outcomes by delivering highly effective, targeted treatments.

Importantly, the research also paves the way for enhanced biomarker development—a critical step in identifying patients who are most likely to respond to mTOR pathway inhibitors. This is a crucial advancement since prior clinical use of these drugs often failed to produce consistent responses, likely due to the absence of robust patient stratification strategies.

The implications extend beyond lymphoma. Given MYC’s involvement in a vast array of cancers, unraveling how GATOR1 controls MYC-driven proliferation could have a sweeping impact on cancer biology and therapy. The study sets a precedent in mapping tumor suppressor networks at a genome scale within living organisms, offering a road map for investigating other cancers where dysregulated metabolism and growth signaling are at play.

Such discoveries are made possible through dedicated research infrastructures and funding support from key Australian bodies including the National Health and Medical Research Council, the Cancer Council of Victoria, and the Victorian Cancer Agency. Collaborative efforts also spanned international support from foundations and research institutions, emphasizing the global commitment to conquering cancer.

As cancer research continues to evolve, studies like this herald a future where genetic and molecular profiling directly informs treatment decisions. The identification of GATOR1 complexes as essential tumor suppressors signals not only a landmark in lymphoma biology but also the promise of precision oncology approaches that could extend survival and improve quality of life for countless patients worldwide.

Subject of Research: Cells

Article Title: Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma

News Publication Date: 21-Aug-2025

Web References:

• https://www.nature.com/articles/s41568-018-0074-8
• https://gco.iarc.who.int/media/globocan/factsheets/cancers/33-hodgkin-lymphoma-fact-sheet.pdf
• https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf

References:
Potts M, Mizutani S, Deng Y, et al. Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma. Nature Communications. 2025; DOI: 10.1038/s41467-025-62615-y.

Keywords: lymphoma, tumor suppressor, GATOR1 complex, CRISPR screening, MYC oncogene, mTORC1 pathway, blood cancer, precision medicine, targeted therapy, genome-wide screening, cellular metabolism, cancer biology

EGFR, long established as a receptor tyrosine kinase integral to cellular proliferation and survival signaling, has been primarily studied for its role at the plasma membrane. Traditionally, ligand binding prompts receptor dimerization and activation of its intrinsic kinase function, sparking a cascade of phosphorylation events and downstream signaling pathways associated with cancer progression and other pathologies. The novelty of this research lies in demonstrating that EGFR retains functional significance within the lysosomal membrane, a site previously thought to be merely a cellular degradation hub rather than a signaling nexus.

At the molecular heart of cellular growth and metabolism is mTORC1 (mechanistic target of rapamycin complex 1), a master regulator that integrates environmental cues such as nutrient availability, energy status, and growth factors to modulate anabolic and catabolic processes. Activation of mTORC1 involves its recruitment to the lysosomal surface where Rheb, a small GTPase, directly activates the complex. Historically, Rheb’s activation was understood to hinge heavily on the TSC1-TSC2 complex’s GTPase activating protein (GAP) activity and presumed upstream growth factor signals transduced via kinase cascades.

What He and colleagues reveal defies this classical logic by showing that EGFR resides on the lysosomal membrane and behaves as a Rheb-GEF—a molecule that facilitates the exchange of GDP for GTP on Rheb—thus promoting its active state independently of its kinase domain. This is significant because it decouples EGFR’s canonical enzymatic function from its newfound regulatory role, illustrating a kinase activity-independent mechanism shaping mTORC1 signaling dynamics. The biochemical data confirm that EGFR’s intracellular domain physically interacts with Rheb, catalyzing its nucleotide exchange without engaging in phosphorylation, an insight that reshapes our molecular blueprint of EGFR-mediated signal transduction.

The implications of this are profound for both fundamental biology and clinical oncology. mTORC1 hyperactivation is implicated in a spectrum of disorders ranging from cancer to metabolic diseases and neurodegeneration. By defining EGFR’s lysosomal localization and its Rheb-GEF function, the study presents a dual-faced nature of EGFR—acting not only as a classic receptor but also as a molecular switch on lysosomes that activates growth-promoting pathways via an unexpected route. This insight could fuel the development of therapeutics that selectively inhibit EGFR’s lysosomal functions without affecting its kinase-dependent signaling at the cell surface, potentially reducing off-target effects and resistance mechanisms.

Moreover, the spatial segregation of EGFR functions adds a new layer of complexity to intracellular signaling networks. The lysosome emerges not only as a degradation center but as a sophisticated signaling platform where growth factor receptors like EGFR can exert kinase-independent effects, dynamically integrating environmental and metabolic signals. The study meticulously employs advanced imaging techniques such as super-resolution microscopy and proximity ligation assays to pinpoint EGFR’s lysosomal residency, while mutational analyses confirm the dispensability of its kinase domain for Rheb GEF functionality.

Intriguingly, this work also challenges the dogma that receptor tyrosine kinases function solely at the plasma membrane or early endosomes. The authors provide compelling evidence that EGFR traffics to lysosomes in a ligand-dependent manner but does not undergo degradation immediately; instead, it adopts a novel function that contributes to cell growth signaling. This highlights an underappreciated versatility in receptor life cycles and the diverse signaling outcomes stemming from subcellular localization.

Biochemical reconstitution assays further delineate the molecular mechanics by which EGFR facilitates GDP-GTP exchange on Rheb. The researchers show that EGFR contains specific domains mediating this interaction, which can be experimentally uncoupled from kinase activity—underscoring the modularity of receptor function. The study also implicates this mechanism in sustaining mTORC1 activation even in contexts where kinase inhibitors targeting EGFR fail to suppress cell proliferation, hinting at a mechanism behind some drug resistance phenomena observed clinically.

From a broader perspective, the identification of EGFR as a lysosomal Rheb-GEF redefines the conceptual framework of how cells coordinate nutrient sensing and growth signaling. Lysosomes, traditionally regarded as terminal degradative organelles, are gaining recognition as command centers orchestrating growth factor signals. EGFR’s role here exemplifies this paradigm shift and suggests that other receptor tyrosine kinases may harbor hidden kinase-independent functions in various subcellular niches.

The therapeutic potential stemming from this finding is enormous. Current EGFR inhibitors primarily target its kinase activity and have limitations including acquired resistance and toxicity. Targeting EGFR’s lysosomal trafficking or its GEF activity on Rheb could offer alternative strategies to modulate mTORC1-driven diseases more precisely. Furthermore, this study advocates for the reevaluation of signaling pathways where kinase-independent activities might account for unanticipated biological effects and drug responses.

On a technical front, the multi-disciplinary approach employed in this study stands out. Combining proteomics, live-cell imaging, structural modeling, and functional assays, the authors construct a convincing narrative of EGFR’s lysosomal role. The discovery was partly facilitated by state-of-the-art techniques enabling visualization of protein interactions at nanometer resolution within intact cells, illustrating the power of integrative methodologies in unraveling complex biological phenomena.

Critically, the research also opens new questions for the scientific community. How is the trafficking of EGFR to lysosomes regulated? What signals dictate its GEF activity versus kinase activity? Are there physiological contexts where this lysosomal function predominates, and how does this influence cellular outcomes such as metabolism, autophagy, or immune responses? Addressing these will be vital to unlocking the full biological and clinical import of this discovery.

In summary, the study by He, Wang, Wei, and colleagues offers a transformative insight into cell signaling by revealing lysosomal EGFR as a Rheb-GEF functioning independently of its kinase activity to activate mTORC1. This dual functionality transcends traditional views of EGFR, showcasing a complex regulatory mechanism crucial for cellular growth control. Beyond deepening fundamental biological knowledge, these findings propose innovative avenues for targeting pathological mTORC1 activation, especially in cancers refractory to current EGFR inhibitors. The lysosomal EGFR-Rheb-mTORC1 axis emerges as a tantalizing molecular target with promising translational potential shaping future therapeutic landscapes.

Subject of Research:

Epidermal growth factor receptor (EGFR) functions at the lysosome as a Rheb-GEF independent of kinase activity to activate the mTORC1 signaling pathway, a master regulator of cellular growth and metabolism.

Article Title:

Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1.

Article References:

He, X., Wang, QX., Wei, D. et al. Lysosomal EGFR acts as a Rheb-GEF independent of its kinase activity to activate mTORC1.
Cell Res (2025). https://doi.org/10.1038/s41422-025-01110-x

Image Credits:

AI Generated